Eli Lilly and Company $LLY Position Boosted by Lewis Asset Management LLC

Lewis Asset Management LLC grew its holdings in Eli Lilly and Company (NYSE:LLY) by 25.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,681 shares of the company’s stock after purchasing an additional 540 shares during the period. Eli Lilly and Company comprises 1.0% of Lewis Asset Management LLC’s portfolio, making the stock its 24th largest holding. Lewis Asset Management LLC’s holdings in Eli Lilly and Company were worth $2,466,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. 10Elms LLP increased its stake in Eli Lilly and Company by 33.3% in the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after buying an additional 10 shares during the period. M.E. Allison & CO. Inc. boosted its stake in shares of Eli Lilly and Company by 0.7% during the 4th quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company’s stock valued at $1,587,000 after buying an additional 10 shares during the period. Tanager Wealth Management LLP grew its holdings in shares of Eli Lilly and Company by 2.6% during the 4th quarter. Tanager Wealth Management LLP now owns 395 shares of the company’s stock valued at $424,000 after acquiring an additional 10 shares in the last quarter. Morey & Quinn Wealth Partners LLC increased its stake in shares of Eli Lilly and Company by 1.5% in the fourth quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company’s stock worth $710,000 after acquiring an additional 10 shares during the last quarter. Finally, Wealthspan Partners LLC increased its stake in shares of Eli Lilly and Company by 0.5% in the fourth quarter. Wealthspan Partners LLC now owns 2,110 shares of the company’s stock worth $2,268,000 after acquiring an additional 10 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on LLY. Bank of America increased their price objective on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a “buy” rating in a report on Tuesday, May 26th. Guggenheim reaffirmed a “buy” rating and issued a $1,183.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, May 5th. Weiss Ratings downgraded Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, May 19th. BMO Capital Markets reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, June 15th. Finally, Royal Bank Of Canada reissued an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,235.07.

Eli Lilly and Company Stock Down 0.1%

LLY stock opened at $1,206.51 on Monday. The firm has a market cap of $1.14 trillion, a PE ratio of 42.86, a PEG ratio of 1.32 and a beta of 0.53. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,215.76. The company has a fifty day simple moving average of $1,036.28 and a 200 day simple moving average of $1,021.13. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same period in the prior year, the business posted $3.34 earnings per share. The business’s quarterly revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 35.8 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The European Medicines Agency’s CHMP recommended approval of Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia across all lines of therapy, which could expand Lilly’s oncology revenue opportunity in the EU. Article Title
• Positive Sentiment: Investors are also focused on Lilly’s obesity franchise, with new details on the Medicare GLP-1 Bridge program that could broaden access to Foundayo (orforglipron) and Zepbound for eligible Medicare Part D patients starting July 1. Article Title
• Positive Sentiment: Management’s expanded access push and continued clinical progress in obesity/diabetes are reinforcing the view that Lilly remains a leader in the weight-loss drug race, supporting bullish sentiment. Article Title
• Neutral Sentiment: Some recent coverage highlights Lilly’s strong pipeline and market leadership, but also notes valuation concerns and a less attractive entry point after the stock’s big run. Article Title
• Neutral Sentiment: News about Lilly launching its cancer drug Tanstrive in India adds another growth angle, but it appears to be a smaller near-term stock driver than the obesity and EU approval updates. Article Title

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.